ChondroFiller® vs
ACI
ACI is the original two-stage autologous chondrocyte implantation, largely superseded in modern practice by MACI but still encountered in older literature and some centres. ChondroFiller® is a single-stage scaffold injection. Here is the honest comparison.

- Collagen scaffold
- Ultrasound-guided injection
- Coats the worn surface
ChondroFiller®
A collagen scaffold injected under ultrasound guidance. It sets in minutes and coats the worn cartilage so your own cells can lay down new tissue.

- Cartilage harvested
- Cells grown in a laboratory
- Implanted under a patch
ACI
Two surgeries: cartilage cells are harvested, grown in a laboratory, then implanted under a patch over the defect.
Quick answer
ChondroFiller® is a single-stage scaffold injection; ACI is the original two-stage cell-based surgical implant under a periosteal patch. ACI (autologous chondrocyte implantation) was the first commercial cell-based cartilage repair technique, originally published in 1994. It involves a cartilage biopsy, several weeks of laboratory cell culture and a second surgery to inject the cells under a periosteal flap sewn over the defect. Most centres have moved to MACI, which uses a collagen membrane instead of periosteum and has fewer complications. ChondroFiller® offers a different alternative again: a single-stage scaffold injection with no cell harvest, no second surgery, no upper age limit and no defect-size limit on the injection.
How it works
ChondroFiller® vs ACI: the key difference
ACI is a two-stage cell-based surgical technique: cartilage cells are harvested at an arthroscopy, cultured in a laboratory for four to six weeks and then injected as a suspension under a periosteal patch sewn over the defect at a second open operation. ChondroFiller® takes a different approach: a sterile collagen scaffold is placed in a single ultrasound-guided injection, and the body’s own cells migrate in over six to twelve months. No periosteal patch. No two-stage surgery. No laboratory phase.
How each treatment works
ChondroFiller®

ChondroFiller® is a sterile type I collagen scaffold. At London Cartilage Clinic it is injected as a liquid into the joint under ultrasound guidance, where it sets within minutes and coats the worn cartilage at the load-bearing surfaces, from a contained focal defect to diffuse surface wear.
The patient’s own cells then migrate into the scaffold and lay down new cartilage matrix over six to twelve months. Single-stage. No cell harvest. No lab phase. No periosteal harvest.
ACI

ACI requires two surgeries. First, an arthroscopy harvests a small piece of cartilage from a non-weight-bearing area. The chondrocytes are sent to a specialist laboratory and expanded in culture for four to six weeks.
A second open or mini-open surgery follows: a piece of periosteum is harvested (usually from the tibia) and sewn over the prepared defect, and the cultured chondrocytes are injected as a suspension under the patch to mature into new cartilage.
Looking ahead
What can you expect over time?
ChondroFiller®
Tissue formation over 6–12 months
ACI
Long-term published cohorts to 10–15 years
Read the comparison in context
Your treatment plan
Number of injections
ChondroFiller®
Typically one injection course, with the box quantity (one, two or three) decided from MRI. ChondroFiller® can be repeated for a separate new defect if needed.
ACI
ACI is a one-off two-stage course. A repeat would require a fresh cartilage biopsy and full cell expansion again. Revision surgery for periosteal hypertrophy is sometimes needed in the months and years after the original procedure.
The treatment journeys
ChondroFiller® pathway
- 1
Suitability and MRI review
Professor Lee reviews your MRI and examination to confirm the injection fits your defect and how many boxes are needed. - 2
One outpatient injection
Delivered in 30 to 45 minutes under ultrasound guidance and local anaesthetic, with the gel setting in minutes. - 3
Home within the hour
There is no brace or crutches unless your medical team specifies otherwise, and a free telephone review follows at six weeks.
ACI pathway
- 1
First surgery: cartilage biopsy
An arthroscopy harvests a small piece of cartilage from a non-weight-bearing area, and the chondrocytes are expanded in a laboratory for four to six weeks. - 2
Second surgery: periosteal patch
A piece of periosteum is sewn over the prepared defect and the cultured chondrocytes are injected under it as a suspension. - 3
Maturation and possible revision
The cells mature into new cartilage, and revision surgery for periosteal hypertrophy is sometimes needed in the months and years afterwards.
Care and precautions
Understanding the risks
BEFORE · DURING · AFTER
Sterile technique.
Image guidance.
Clear aftercare.
Very different risk profiles. ChondroFiller® at London Cartilage Clinic is an ultrasound-guided outpatient injection with routine IV antibiotic cover. The most serious risk is joint infection, which is rare.
ACI involves two surgeries with the standard surgical risks (infection, deep-vein thrombosis, anaesthetic complications) at each operation, plus procedure-specific issues: periosteal hypertrophy (overgrowth of the patch requiring reoperation), graft delamination, donor-site morbidity at the periosteum and a prescriptive rehabilitation programme. These were the main drivers behind the field moving from ACI to MACI.
Practical planning and safety
Questions to raise before either option
Ask about temporary soreness or swelling, the risk of joint infection, and anything specific to your health and current medicines. Ask who you contact if something does not feel right afterwards.
Who may suit ChondroFiller →Aftercare depends on the route
After the ChondroFiller injection there is no brace and no crutches unless your medical team specifies otherwise. Keyhole surgery follows the rehabilitation protocol set out by the manufacturer, with a brace for 48 hours and weight rebuilt over about six to eight weeks.
Read the injection aftercare guide →Your joint, your goals
Where does each option fit?

ACI is appropriate for symptomatic knee cartilage defects in adults with otherwise reasonably preserved joints, in centres still offering the procedure. In modern practice, MACI is usually offered in preference to ACI for the same indications. If you have been recommended ACI specifically, it is worth asking whether MACI is an option at the same centre.
ChondroFiller® is appropriate for cartilage wear in the joint, whether a contained focal defect or diffuse surface wear, with no upper age limit and no defect-size limit on the injection. It is delivered as an injection, which suits patients who want to avoid open surgery, a periosteal patch and a two-stage pathway. See who is suitable for ChondroFiller?
What would make the difference for you?
Questions worth taking to your consultation, so the discussion stays on your joint.
- 01What is causing my joint pain?The diagnosis and your imaging decide which treatments are worth discussing.
- 02Is there a defect, or wear across the joint?Ask how the pattern of cartilage damage shapes the recommendation.
- 03What improvement are we aiming for?Agree realistic goals for pain, function and timescale before you choose.
- 04What happens if I need more help later?Ask which options stay open if symptoms return or progress.
Planning the cost
Compare the complete care package
Ultrasound-guided injection
ChondroFiller®
From · one box
£3,000
Two boxes £5,500; three boxes £8,000. The consultation is charged separately.
Full ChondroFiller pricing →At London Cartilage Clinic, ChondroFiller® costs from £3,000 for one box, £5,500 for two and £8,000 for three, with the consultation charged separately. See the ChondroFiller® cost guide.
Where ACI is still offered privately it typically costs £25,000 to £35,000 in the UK because the cell processing and two surgeries are inherently expensive. NHS availability of ACI specifically is now very limited; most NHS centres have moved to MACI for cell-based cartilage repair.
The headline cost gap is meaningful, but the more important question is whether a cell-based two-stage operation or a single-stage scaffold injection is the right answer for the defect on imaging.
Making a recommendation
When each option may make sense
ChondroFiller®
A discussion to have
- A focal cartilage defect on MRI where a single-stage scaffold injection is reasonable.
- You want to avoid a two-stage operation, periosteal harvest and the historical complications of ACI.
- You are looking at a private-pay cell-based pathway and want to understand the alternatives.
ACI
A discussion to have
- ACI is increasingly recommended only in specific centres where the surgeon has long experience with the technique and a particular reason to prefer it over MACI.
- For most patients considering a cell-based cartilage implant, MACI is the more current option: see ChondroFiller® vs MACI for that comparison.
Choosing another path
When another approach may be better
ChondroFiller®
A reason to reconsider
- Very large or multi-zone defects where a surgical cell-based or co-delivery procedure is more appropriate.
- Unstable subchondral bone, significant bone marrow oedema or a joint where imaging review points to replacement; bone-on-bone wear on its own is not the deciding factor.
ACI
A reason to reconsider
- Small focal defects where a two-stage cell-based pathway is over-treatment.
- Most modern indications, where MACI is the preferred cell-based option over original ACI.
- Patients unwilling to accept the periosteal-patch-specific risks or unable to complete the rehabilitation programme.
The bottom line
ACI was the original cell-based cartilage-repair technique and still has a place in specialist centres, but modern practice has largely moved on to MACI for the same indications. ChondroFiller® offers a different alternative again: a single-stage scaffold injection without cell harvest, periosteal patch or two-stage surgery. The right answer is decided from imaging and a clear conversation about trade-offs, not from a default label.
Common questions
01What is the difference between ACI and MACI?
ACI is the original technique: cultured cartilage cells injected as a suspension under a periosteal patch sewn over the defect. MACI is the modern variant: the same cultured cells are pre-loaded onto a porcine collagen membrane and the membrane is implanted into the defect. MACI was developed to reduce the periosteal-patch-specific complications of ACI.
02Should I have ACI today, or is it outdated?
ACI is still offered in specific specialist centres, but in modern UK practice MACI is usually preferred for the same indications. If ACI specifically has been recommended to you, it is worth asking whether MACI is available at the same centre, and what the rationale is for ACI over MACI in your case.
03Is the donor-site morbidity from the periosteum a real concern?
It is a recognised issue in published ACI series: pain at the periosteal harvest site and occasional functional impact. It is one of the reasons MACI, which uses a collagen membrane instead of harvested periosteum, became the more common cell-based technique. ChondroFiller® avoids the question entirely because there is no harvest.
04Can ChondroFiller® be used after ACI has failed?
Sometimes yes: where the failed ACI has left a contained defect with reasonably stable surrounding tissue and no significant overgrowth or bony irregularity, ChondroFiller® can occasionally be considered. We review the post-ACI imaging before deciding.
05How does the long-term evidence compare?
ACI has the longest cell-based cartilage-repair publication history because it was the first commercially available technique, with cohorts out to ten and fifteen years. ChondroFiller® has a younger publication record, with maintained outcomes (IKDC, Harris Hip Score, MOCART MRI) at five years and over 19,000 cases of clinical use across joints. See the ChondroFiller® clinical evidence page.
06Why would I choose ChondroFiller® over the cell-based options?
For some patients, the single-stage scaffold injection avoids the two-stage surgical pathway, the cell-harvest step, the periosteal patch (in ACI) and the cost of cell processing. For other patients, particularly with larger or more demanding defects, a cell-based pathway is the better answer. The decision is made at consultation with imaging review.







